Loading...

Sachdev Thomas, MD

TitleAssistant Professor
SchoolUCSF School of Medicine
DepartmentDean's Office
Address550 16th. Street
San Francisco CA 94158
Phone559-499-6500
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Jatoi A, Qin R, Satele D, Dakhil S, Kumar P, Johnson DB, Thomas S, Stella PJ, Castillo J, Li M, Fernandez-Zapico M. "Enjoy glass of wine before eating:" a randomized trial to test the orexigenic effects of this advice in advanced cancer patients. Support Care Cancer. 2016 Sep; 24(9):3739-46. PMID: 27039205.
      View in: PubMed
    2. Ready NE, Pang HH, Gu L, Otterson GA, Thomas S, Miller AA, Baggstrom M, Masters GA, Graziano SL, Crawford J, Bogart J, Vokes EE. Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance). J Clin Oncol. 2015 May 20; 33(15):1660-5. PMID: 25732163; PMCID: PMC4429175 [Available on 05/20/16].
    3. Zhao Y, Foster NR, Meyers JP, Thomas S, Northfelt DW, Rowland KM, Mattar BI, Johnson DB, Molina JR, Mandrekar SJ, Schild SE, Bearden JD, Aubry MC, Adjei AA. A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321. J Thorac Oncol. 2015 Jan; 10(1):172-80. PMID: 25247339; PMCID: PMC4320011 [Available on 01/01/16].
    4. Jain N, Curran E, Iyengar NM, Diaz-Flores E, Kunnavakkam R, Popplewell L, Kirschbaum MH, Karrison T, Erba HP, Green M, Poire X, Koval G, Shannon K, Reddy PL, Joseph L, Atallah EL, Dy P, Thomas S, Smith SE, Doyle LA, Stadler WM, Larson RA, Stock W, Odenike O. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res. 2014 Jan 15; 20(2):490-8. PMID: 24178622; PMCID: PMC4310865.
    5. Campbell NP, Kunnavakkam R, Leighl N, Vincent MD, Gandara DR, Koczywas M, Gitlitz BJ, Agamah E, Thomas S, Stadler WM, Vokes EE, Kindler HL. Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium. Lung Cancer. 2012 Oct; 78(1):76-80. PMID: 22831987; PMCID: PMC4319647.
    6. Traynor AM, Lee JW, Bayer GK, Tate JM, Thomas S, Mazurczak M, Graham DL, Kolesar JM, Schiller JH. A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503. Invest New Drugs. 2010 Feb; 28(1):91-7. PMID: 19238328; PMCID: PMC3045859.
    7. Hines SL, Mincey BA, Sloan JA, Thomas S, Chottiner E, Loprinzi CL, Carlson MD, Atherton PJ, Salim M, Perez EA. Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. J Clin Oncol. 2009 Mar 1; 27(7):1047-53. PMID: 19075260; PMCID: PMC2667810.
    8. Jatoi A, Dakhil SR, Foster NR, Ma C, Rowland KM, Moore DF, Jaslowski AJ, Thomas S, Hauge MD, Flynn PJ, Stella PJ, Alberts SR. Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B). J Thorac Oncol. 2008 May; 3(5):516-20. PMID: 18449005; PMCID: PMC3929582.
    9. Lee RT, Beekman KE, Hussain M, Davis NB, Clark JI, Thomas S, Nichols KF, Stadler WM. A University of Chicago consortium phase II trial of SB-715992 in advanced renal cell cancer. Clin Genitourin Cancer. 2008 Mar; 6(1):21-4. PMID: 18501078; PMCID: PMC2704464.
    10. Delaunoit T, Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Findlay BP, Thomas S, Salim M, Schaefer PL, Stella PJ, Green E, Mailliard JA. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741. Cancer. 2004 Nov 15; 101(10):2170-6. PMID: 15470715.
      View in: PubMed
    Sachdev's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _
    Back to TOP